Intimation of the certificate received from RTA in terms of Regulation 74(5) of the SEBI (Depositories and Participants Regulations), 2018.

Evonile Pharma Limited (formerly known as Novartis India Limited) October 13, 2026 The Secretary BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code - 500672 Sub.: Certificate in terms of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the Quarter and Half Year ended September 30, 2026, issued to Evonile Pharma Limited (formerly known as Novartis India Limited) (“The Company”). Dear Sir/ Madam, Pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby enclose the certificate dated October 13, 2026, issued by MUFG Intime India Private Limited (formerly known as Link Intime India Private Limited), the Registrar to the Issue and Share Transfer Agent (“RTA”) of the Company, for the quarter and half year ended September 30, 2026. You are requested to take the above information on record. Thank you. Yours Sincerely, For Evonile Pharma Limited (formerly known as Novartis India Limited) Chandni Maru Company Secretary and Compliance Officer A60291 Encl.: as above Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.evonilepharma.com